Zhang Quan-Guang, Wang Rui-Min, Han Dong, Yang Li-Cai, Li Jie, Brann Darrell W
Developmental Neurobiology Program, Institute of Molecular Medicine and Genetics, and Department of Neurology, Medical College of Georgia, Augusta, GA 30912, USA.
Neurosci Res. 2009 Mar;63(3):205-12. doi: 10.1016/j.neures.2008.12.010.
Previous work has demonstrated that ischemic preconditioning neuroprotection is associated with inhibition of JNK pathway activation. The present study was designed to examine the hypothesis that the suppression of JNK3 activation by preconditioning is mediated by NMDA receptors and crosstalk between ERK1/2 and JNK3. Preconditioning (3 min ischemia) 2 days before global cerebral ischemia (8-min) markedly decreased neuronal degeneration in hippocampus CA1, an effect abolished by pretreatment with the NMDA receptor antagonist, MK-801. Furthermore, preconditioning abolished cerebral ischemia-induced JNK3 activation and enhanced ERK1/2 activation, an effect reversed by MK-801. Due to the inverse relationship between ERK1/2 and JNK3 activation following preconditioning, we hypothesized that ERK1/2 may regulate JNK3 activation following preconditioning. In support of this contention, pretreatment with the MEK inhibitor, PD98059 significantly attenuated preconditioning-induced ERK1/2 phosphorylation, and strongly reversed preconditioning down-regulation of JNK3 phosphorylation. This finding suggests that ERK1/2 signaling is responsible for preconditioning-induced down-regulation of JNK3 activation. Western blot analysis and immunohistochemistry further demonstrated that preconditioning, in an NMDA-dependent manner, enhanced activation of the pro-survival factors, p-CREB and Bcl-2, while attenuating activation of putative pro-death factors, p-c-Jun and Fas-L in the hippocampus CA1. As a whole, the study demonstrates that preconditioning attenuation of pro-death JNK3 in the hippocampus CA1 following global cerebral ischemia is mediated by NMDA receptor-induced crosstalk between ERK1/2 and JNK3. The ERK1/2-mediated reduction of JNK3 activation leads to enhanced pro-survival signaling (P-CREB and Bcl-2 induction) and attenuation of pro-death signaling (p-c-Jun and Fas-L), with subsequent induction of ischemic tolerance.
先前的研究表明,缺血预处理神经保护作用与JNK信号通路激活的抑制有关。本研究旨在验证以下假设:预处理对JNK3激活的抑制作用是由NMDA受体介导的,并且是ERK1/2与JNK3之间相互作用的结果。在全脑缺血(8分钟)前2天进行预处理(3分钟缺血),可显著减少海马CA1区的神经元变性,而NMDA受体拮抗剂MK-801预处理可消除这种作用。此外,预处理可消除脑缺血诱导的JNK3激活,并增强ERK1/2激活,而MK-801可逆转这种作用。由于预处理后ERK1/2与JNK3激活呈负相关,我们推测ERK1/2可能在预处理后调节JNK3激活。支持这一观点的是,MEK抑制剂PD98059预处理可显著减弱预处理诱导的ERK1/2磷酸化,并强烈逆转预处理对JNK3磷酸化的下调作用。这一发现表明,ERK1/2信号通路负责预处理诱导的JNK3激活下调。蛋白质免疫印迹分析和免疫组织化学进一步表明,预处理以NMDA依赖的方式增强了海马CA1区促生存因子p-CREB和Bcl-2的激活,同时减弱了假定的促死亡因子p-c-Jun和Fas-L的激活。总体而言,该研究表明,全脑缺血后海马CA1区促死亡JNK3的预处理减弱是由NMDA受体诱导的ERK1/2与JNK3之间的相互作用介导的。ERK1/2介导的JNK3激活减少导致促生存信号增强(P-CREB和Bcl-2诱导)和促死亡信号减弱(p-c-Jun和Fas-L),随后诱导缺血耐受。